Pathogenetic therapy for psoriasis and psoriatic arthritis

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Serov D.N.

Moskovskiĭ nauchno-prakticheskiĭ tsentr dermatovenerologii i kosmetologii DZM

Pathogenetic therapy for psoriasis and psoriatic arthritis

Authors:

Potekaev N.N., Serov D.N.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2012;10(4): 4‑9

Read: 1669 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Potekaev NN, Serov DN. Pathogenetic therapy for psoriasis and psoriatic arthritis. Russian Journal of Clinical Dermatology and Venereology. 2012;10(4):4‑9. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper gives the present view of the immunopathogenesis and therapy of psoriasis and psoriatic arthritis, by using the genetically engineered agent Etanercept.

Keywords:

psoriasis

psoriatic arthritis

tumor necrosis factor

Etanercept

Authors:

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Serov D.N.

Moskovskiĭ nauchno-prakticheskiĭ tsentr dermatovenerologii i kosmetologii DZM

Close metadata

References:

Reich K., Kruger K., Mossner R., Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 5: 1040-1047.
Kurdina M.I. Metodicheskie rekomendatsii. Ministerstvo zdravookhraneniya RF. Gosudarstvennoe uchebno-nauchnoe uchrezhdenie "Fakul'tet fundamental'noi meditsiny Moskovskogo gosudarstvennogo universiteta im. M.V. Lomonosova". M 2011.
Molochkov V.A., Badokin V.V., Al'banova V.I., Volnukhin V.A. Psoriaz i psoriaticheskii artrit. M 2007.
Kurdina M.I. Novoe v sistemnoi terapii psoriaza. Klin dermatol i venerol 2011; 5: 54-59.
Christophers E., Barker J.N., Griffiths C.E. et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in european dermatology clinics. J Eur Acad Dermatol Venereol 2009; 24: 5: 548-554.
Smith C.H., Anstey A.V., Barker J.N. et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 5: 987-1019.
Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin. Arthr Rheum 2010; 40: 233-240.
Batpenova G.R., Kotlyarova T.V., Tarkina T.V. Patogeneticheskaya terapiya psoriaza. Metodicheskie rekomendatsii. Astana 2011.
Mitoma H., Horiuchi T., Tsukamoto H. et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthr Rheum 2008; 58: 5: 1248-1257.
Dhillon S., Lyseng-Williamson K.A., Scott L.J. Etanercept: a review of its use in the management of rheumatoid arthritis. Drugs 2007; 7: 1211-1241.
Bachmann F., Kokolakis G., Sterry W., Philipp S. Etanercept: overview of clinical experience in the treatment of psoriasis and psoriatic arthritis. Int J Rheumatol 2011; 6: 2: 135-168.
Bongartz T., Sutton A.J., Sweeting M.J. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
Sterry W., Ortonne J.P., Kirkham B. et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: 147.
Altomare G., Ayala F., Berardesca E. et al. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol Ther 2008; 21: 1-14.
Strohal R., Puig L., Chouela E. et al. The efficacy and safety of etanercept when used with as - needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatol Treat 2012; 1: 175-194.
Papp K., Poulin Y., Bissonnette R. et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012; 66: 2: e33-e45.
Wyeth-Pfizer: Fachinformation Enbrel stand 05/2010. Enbrel. Pfizer - NY (USA) 2010.
Caporali R., Bobbio-Pallavicini F., Atzeni F. et al. Safety of tumor necros factor a blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthr Care Res 2010; 62: 749-754.
Patel R.V., Clark L.N., Lebwohl M., Weinberg J.M. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60: 1001-1017.

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.